What are the indications, dosing schedule, contraindications, pregnancy considerations, side effects, and alternative options for Engerix‑B (recombinant hepatitis B surface antigen vaccine)?

Engerix-B: Comprehensive Clinical Guide

Engerix-B is a recombinant hepatitis B vaccine indicated for active immunization against hepatitis B virus infection in all age groups, with universal vaccination now recommended for all adults aged 19-59 years and specific populations at any age. 1

Indications

Universal vaccination is recommended for:

• All adults aged 19-59 years (including pregnant persons)
• Adults ≥60 years with risk factors for hepatitis B
• Adults ≥60 years without known risk factors may also receive vaccination 1, 2

Specific high-risk populations include:

• Neonates (especially those born to HBsAg-positive mothers)
• Healthcare workers with occupational exposure
• Persons on hemodialysis
• Immunocompromised individuals
• Persons with chronic liver disease
• Household contacts of HBV carriers 1, 3

Dosing Schedule

Standard Populations

Ages 11-19 years:

• Dose: 10 μg (0.5 mL)
• Schedule: 0,1, and 6 months 1

Adults ≥20 years:

• Dose: 20 μg (1 mL)
• Schedule: 0,1, and 6 months 1

Special Populations

Adults on hemodialysis and immunocompromised adults ≥20 years:

• Dose: 40 μg (2 mL) - administered as single 2-mL dose or two 1-mL doses
• Schedule: 4 doses at 0,1,2, and 6 months 1

This is a critical distinction—dialysis patients require both higher doses AND an additional fourth dose compared to standard populations.

Interrupted Schedules

If vaccination is interrupted, do NOT restart the series: 1

• If interrupted after first dose: give second dose as soon as possible; separate second and third doses by ≥8 weeks
• If only third dose delayed: administer as soon as possible
• Minimum intervals: 4 weeks between doses 1-2; ≥8 weeks between doses 2-3; ≥16 weeks between doses 1-3
• Doses given ≤4 days before minimum interval are considered valid

Contraindications

Based on FDA labeling 4, absolute contraindications include:

• Severe allergic reaction (anaphylaxis) to any vaccine component
• Severe allergic reaction after a previous dose of any hepatitis B vaccine

Pregnancy Considerations

Engerix-B is specifically recommended as the preferred hepatitis B vaccine for pregnant persons. 1

The rationale is clear: newer vaccines (Heplisav-B and PreHevbrio) have insufficient data to inform vaccine-associated risks in pregnancy. Engerix-B, along with Recombivax HB and Twinrix, should be used for pregnant persons needing HepB vaccination 1. The vaccine has been safely administered during pregnancy with no adverse effects on pregnancy outcomes or offspring 5.

Side Effects and Tolerability

Engerix-B is generally well tolerated with an excellent safety profile: 6, 3

Most common adverse events:

• Mild soreness at injection site (most frequent)
• Local reactions (pain, redness, swelling)
• Systemic reactions are uncommon

Important safety considerations:

• Syncope can occur: Observe patients for 15 minutes post-vaccination 4
• Apnea risk in premature infants: Consider hospitalization for 48-72 hours of respiratory monitoring for very premature infants (born <28 weeks gestation) 4
• Tolerability profile similar to other recombinant hepatitis B vaccines 6, 3

Alternative Vaccine Options

For standard adult populations (non-pregnant, non-dialysis):

1. Heplisav-B (≥18 years)

   • 2-dose series at 0 and 1 month
   • Advantage: Faster completion, higher seroprotection rates 7
   • Cannot use in: pregnancy, hemodialysis patients 1

2. Recombivax HB (all ages)

   • Similar dosing schedules to Engerix-B
   • Comparable efficacy 6, 3

3. PreHevbrio (≥18 years)

   • Three-antigen vaccine
   • 3-dose series at 0,1, and 6 months
   • Cannot use in: pregnancy, hemodialysis patients 1

4. Twinrix (≥18 years)

   • Combined hepatitis A and B vaccine
   • Standard: 0,1,6 months OR Accelerated: 0 days, 7 days, 21-30 days, and 12 months
   • Can use in pregnancy 1

Vaccines are interchangeable: Different hepatitis B vaccines can be used to complete a series if the same vaccine is unavailable 8

Clinical Pearls and Pitfalls

Key advantages of Engerix-B:

• Only vaccine with established safety data in pregnancy
• Only vaccine (along with Recombivax HB) with established efficacy in hemodialysis patients
• Extensive 40-year safety record 9
• High seroprotection rates (93-100%) after complete series 6

Common pitfalls to avoid:

• Using standard adult dose (20 μg) in dialysis patients—they require 40 μg
• Forgetting the fourth dose in dialysis patients at 2 months
• Restarting series when interrupted—just continue with appropriate intervals
• Withholding vaccination from pregnant persons—Engerix-B is safe and recommended

Duration of immunity:

• Protective immunity persists for at least 10 years in immunocompetent individuals 3
• Routine booster doses are not currently recommended for immunocompetent persons
• Anti-HBs titers decline over time but immune memory typically provides protection 6

Efficacy:

• 95-99% protective efficacy against HBsAg carriage in high-risk populations 3
• Excellent protection in neonates born to HBV-positive mothers when combined with HBIG 6